PIK3CA and breast carcinoma: Although we have not evaluated the effect of PIK3CA helical domain mutation on PEPDG278D activity in CRC cells, we previously showed that PIK3CA helical domain mutation does not confer resistance to PEPDG278D in HER2-positive breast cancer cells [21].